Latest Breaking News On - Duke vitreoretinal fellowship program - Page 2 : comparemela.com

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shankar musunuriLejla vajzovicTarun upadhyayDuke university school of medicineOcugen incUniversity of miamiHead of clinical developmentHead of communicationsHead of researchBascom palmer eye instituteExchange commissionRetina foundation of theRetinitis pigmentosaLeber congenitalAnalyst eventChief scientific officer

Ocugen to Host Virtual Investor & Analyst Event on

Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis.

Lejla vajzovicTarun upadhyayShankar musunuriOcugen incExchange commissionUniversity of miamiHead of communicationsHead of researchDuke university school of medicineRetina foundation of theHead of clinical developmentBascom palmer eye instituteAnalyst eventChief scientific officerClinical developmentMedical affairs

Ocugen (OCGN) Reports Positive Clinical Study Update from the Phase 1/2 Trial of OCU400

Ocugen (OCGN) Reports Positive Clinical Study Update from the Phase 1/2 Trial of OCU400
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Los angelesUnited statesShankar musunuriLejla vajzovicTarun upadhyayDavid boyerHead of researchAboutocugen inc ocugenKeck school of medicine los angelesDuke university school of medicineOcugen incRetina foundation of theTiffany hamiltonhead of communicationsRetina vitreous associates medical groupRetinitis pigmentosaChief executive officer

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity .

Los angelesUnited statesTarun upadhyayDavid boyerLejla vajzovicShankar musunuriRetina vitreous associates medical groupOcugen incRetina foundation of theDuke university school of medicineAboutocugen incKeck school of medicine los angelesHead of communicationsHead of researchBest corrected visual acuityMulti luminance mobility testing

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier

FavorablesafetyandtolerabilityprofileofOCU400investigationaldrugproductin RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-Luminance

Los angelesUnited statesTarun upadhyayLejla vajzovicDavid boyerShankar musunuriHead of researchOcugen incRetina vitreous associates medical groupHead of communicationsKeck school of medicine los angelesRetina foundation of theDuke university school of medicineBest corrected visual acuityMulti luminance mobility testingLow luminance visual acuity